Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck announced positive topline results from its Phase 2b/3 trial of clesrovimab (MK-1654), an investigational RSV preventative monoclonal antibody for infants, meeting primary safety and efficacy endpoints including reducing medically attended lower respiratory infections caused by RSV through Day 150.